
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is setting itself up for future success with its diverse portfolio of clinical-stage programs, particularly the recent release of positive Phase 1 data for SEP-631 in the treatment of chronic spontaneous urticaria (CSU). With a planned Phase 2b trial for SEP-631 in the second half of 2026 and a promising TSHR negative allosteric modulator (NAM) program in development for the treatment of Graves' disease and thyroid eye disease, Septerna's prospects look strong. Though conservative, with a projected price objective of $35 per share, there are potential risks to consider such as delays in clinical development, setbacks in trials, and partnership risks with Novo Nordisk.
Bears say
Septerna is currently in a phase of discovery and development with its GPCR oral small molecule drug discovery platform. While it has a diverse pipeline of product candidates targeting various therapeutic areas, the company's ongoing activities and partnerships do not provide a strong indication of future success or profitability. As such, the company's financial outlook is concerning and may not justify investing in the stock.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares